Circulating Sfrp5 Is a Signature of Obesity-Related Metabolic Disorders and Is Regulated by Glucose and Liraglutide in Humans
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
CONTEXT: Secreted frizzled-related protein-5 (Sfrp5) is a novel adipocyte-secreted hormone that has been shown to link obesity with diabetes. Studies in mice have revealed that Sfrp5 represents a potential target for the control of obesity-linked abnormalities in glucose homeostasis. OBJECTIVE: Our objective was to gain insight into the physiological role of circulating Sfrp5 in humans. PATIENTS AND DESIGN: We conducted a series of cross-sectional and interventional studies of the general population and outpatients of the Internal Medicine Department at the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. Subjects included 104 healthy subjects, 101 with impaired glucose tolerance, and 112 with newly diagnosed type 2 diabetes mellitus and, in a separate study, 30 healthy women, and 32 women with polycystic ovarian syndrome (PCOS). Oral glucose tolerance test and euglycemic-hyperinsulinemic clamp were performed to assess glucose tolerance and insulin sensitivity. RESULTS: Circulating Sfrp5 was significantly lower in both impaired glucose intolerance and newly diagnosed type 2 diabetes mellitus than in individuals with normal glucose tolerance (P < 0.01). Overweight/obese subjects had significantly lower Sfrp5 levels than lean individuals (P < 0.01), but females had higher Sfrp5 levels than males (P < 0.05). In a separate study, Sfrp5 levels were lower in PCOS women than healthy women (P < 0.05). Moreover, circulating Sfrp5 correlated with markers of adiposity, including body mass index, waist-to-hip ratio, percent body fat, homeostasis model assessment of insulin resistance, lipid profile, and adiponectin. Hyperglycemia decreased circulating Sfrp5 levels, whereas liraglutide increased Sfrp5 levels. In the euglycemic-hyperinsulinemic state, circulating Sfrp5 was significantly decreased in healthy women but not in PCOS women. CONCLUSIONS: We conclude that circulating Sfrp5 is likely to play a major role in insulin resistance in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adipose Tissue as an Endocrine Organ
Kershaw, E. E., & Flier, J. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0395 · Cited by 5,522
Adipose tissue, adipokines, and inflammation
Fantuzzi, G. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.02.023 · Cited by 2,606
Secreted antagonists of the Wnt signalling pathway
Kawano, Y., & Kypta, R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00623 · Cited by 1,584
Polycystic ovarian syndrome: Pathophysiology, molecular aspects and clinical implications
Diamanti-Kandarakis, E. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000598 · Cited by 294
Insulin Resistance in Type 2 Diabetes - Role of the Adipokines
Arner, P. (2005) · Current Molecular Medicine · doi:10.2174/1566524053766022 · Cited by 201
Cited by
Jung, U., & Choi, M.-S. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15046184 · Cited by 1,880
Adipocytokines in Obesity and Metabolic Disease
Cao, H. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0339 · Cited by 705
Fuster, J. J., Ouchi, N., Gokce, N., & Walsh, K. (2016) · Circulation Research · doi:10.1161/circresaha.115.306885 · Cited by 664
Sex dimorphism and depot differences in adipose tissue function
White, U. A., & Tchoukalova, Y. D. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.05.006 · Cited by 284
Recinella, L., Orlando, G., Ferrante, C., Chiavaroli, A., Brunetti, L., & Leone, S. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.578966 · Cited by 261
Bray, J. J. H., Foster‐Davies, H., Salem, A., Hoole, A. L., Obaid, D. R., Halcox, J. P. J., & Stephens, J. W. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14399 · Cited by 194
Jensterle Sever, M., Kocjan, T., Pfeifer, M., Kravos, N. A., & Janez, A. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0797 · Cited by 175
Muise, E. S., Souza, S., Chi, A., Tan, Y., Zhao, X., Liu, F., Dallas-yang, Q., Wu, M., Sarr, T., Zhu, L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073011 · Cited by 57
“There are also conflicting reports on the role of Sfrp5 in human adipose biology [34,35], thus the biological impact of a down-regulation of this gene by FGF21 warrants further investigation.”
BackgroundSelf-citationCurrent Perspectives on Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome
Wang, D., & He, B. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s362424 · Cited by 28
“56 Obesity reduces the level of SFRP5 and its anti-inflammatory effect in the liver; 57 it also reduces the level of NRG4 and weakens the regulatory effect of NRG4 on hepatic lipogenesis.”
Wu, W., Chen, Z., Han, J., Qian, L., Wang, W., Lei, J., & Wang, H. (2023) · Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity · doi:10.1007/s40519-023-01593-w · Cited by 18
Oztas, E., Ozler, S., Ersoy, E., Ersoy, A. O., Tokmak, A., Ergin, M., Uygur, D., & Danisman, N. (2016) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2015.1052399 · Cited by 16
“between type 2 diabetes mellitus and Sfrp-5 [19,20] consistent with the results of our study.”
MethodResult
Metadata
- Authors
- Hu, W., Li, L., Yang, M., Luo, X., Ran, W., Liu, D., Xiong, Z., Liu, H., & Yang, G.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-01
- Volume
- 98
- Issue
- 1
- Pages
- 290-298
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2058461923
- Cited by
- 125
- References
- 5
- FWCI
- 6.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.